Cowen Upgrades Hologic (HOLX) to “Outperform”
Hologic (NASDAQ:HOLX) was upgraded by investment analysts at Cowen from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday.
A number of other research firms also recently commented on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Hologic in a report on Tuesday, December 5th. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and increased their price target for the stock from $45.00 to $50.00 in a report on Friday. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Thursday, November 9th. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price target (down from $48.00) on shares of Hologic in a report on Monday, October 9th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $42.00 price target on shares of Hologic in a report on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Hologic presently has an average rating of “Buy” and a consensus price target of $47.62.
Shares of Hologic (NASDAQ:HOLX) opened at $42.69 on Monday. The company has a market capitalization of $11,768.93, a PE ratio of 21.13, a P/E/G ratio of 2.06 and a beta of 0.95. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80.
In other news, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Karleen Marie Oberton sold 1,256 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $39.29, for a total value of $49,348.24. Following the transaction, the vice president now directly owns 9,406 shares of the company’s stock, valued at $369,561.74. The disclosure for this sale can be found here. Insiders have sold 28,833 shares of company stock valued at $1,107,270 over the last ninety days. 0.79% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. Grove Bank & Trust boosted its position in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 1,535 shares during the period. Hall Laurie J Trustee boosted its position in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after buying an additional 225 shares during the period. Commonwealth Bank of Australia boosted its position in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 600 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic during the second quarter worth about $191,000. Finally, National Asset Management Inc. acquired a new position in shares of Hologic during the second quarter worth about $203,000. 98.08% of the stock is owned by institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.